U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
Survivors of clergy sexual abuse are urging the Vatican to adopt the same zero-tolerance policy that it approved for the U.S.
What role did partnerships with area organizations play in securing Indiana Tech’s $21.5 million Lilly Endowment grant?
Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.